Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

January 6, 2003

Slides

Cozaar® (losartan potassium) Tablets

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

COZAAR (losartan) in Hypertensive Patients with Left Ventricular Hypertrophy, Dr. Jeffrey Tucker, MD, Merck Research Lab. (HTM) (PPT)

Backup Information, Merck Research Lab. (PDF)

Backup Information, Merck Research Lab. (PDF)

Analysis of LIFE Study by Ethnic Demographic Subgroup, John Lawrence, FDA (HTM) (PPT)